By WuXi Content Team

WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International Convention 2019.

The BIO International Convention is hosted annually by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

This year’s event has brought together more than 16,000 attendees from around the globe for unparalleled partnering, education, networking opportunities. Each year the Convention picks a key theme and 2019’s, aptly for WuXi, is “It Starts With One”. 

“Scientific progress begins with one idea, one theory, one trial, one success. The small initiatives of today—the incremental investments of time, energy, and dedication that each of us makes—can have a global impact on tomorrow.”

At WuXi, we also believe in the power of ONE – the power of one individual, one organization, one idea, or just one dream – is what the future can, and will be built upon.

Taking place one evening during the convention, WuXi’s Partner Reception was held at the Franklin Institute in Philadelphia and attended by guests from more than 500 organizations.

The Reception’s highlight was undoubtedly the presence of Philadelphia Mayor James Kenney, who presented WuXi with a recognition citation.

In his speech, Mayor Kenney expressed his appreciation for WuXi’s outstanding contribution to the world’s biotech industry and how he expected the collaboration between WuXi and its partners to continue to make a vital difference to patients around the world.

Philadelphia itself and the surrounding tri-state area is a remarkable biotechnology and life sciences community. This hub of innovation is of vital economic importance to the states of Delaware, New Jersey, and Pennsylvania. The area’s vast array of leading universities and research institutions has fostered an attractive collaborative environment that we too have embraced.

Since coming to Philadelphia more than ten years ago, WuXi has diligently built, and served the tri-state area with its world-leading Contract Development and Manufacturing Organization (CDMO) services that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. With WuXi Advanced Therapies enabling capability, we are winning trust from increasing numbers of partners.

Iovance Biotherapeutics, the California-headquartered late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, decided to expand its relationship with WuXi’s Advanced Therapies Business Unit (WuXi ATU). “Being able to expand our relationship in order to broaden patient access to our treatments is very important to us. WuXi has been a strong partner in developing the Iovance TIL product and we look forward to further expansion of our ongoing relationship,” said Maria Fardis, President and CEO of Iovance.

Over the next few years, Iovance plans to invest roughly $75 million to build a 136,000-square-foot facility in the Philadelphia Navy Yard just next to WuXi Advanced Therapies, which manufactures TIL products for Iovance at its a 55,000-square-foot manufacturing facility for cell therapies.

By the end of this year, the total area of WuXi’s R&D and manufacturing facilities in Philadelphia are expected to exceed 400,000 sq. ft., which will jointly create a key center of WuXi to enable gene and cell therapies globally.

WuXi looks forward to further strengthening cooperation with its partners both from academia and the industry in Philadelphia, which is at the forefront of gene and cell therapies.

Together we can achieve the dream that “every drug can be made and every disease can be treated.”